LOCALLY ADVANCED URETHRAL UROTHELIAL CARCINOMA
Clinical trials for LOCALLY ADVANCED URETHRAL UROTHELIAL CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new LOCALLY ADVANCED URETHRAL UROTHELIAL CARCINOMA trials appear
Sign up with your email to follow new studies for LOCALLY ADVANCED URETHRAL UROTHELIAL CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Personalized cancer fight: matching drugs to your Tumor's genetic fingerprint
Disease control OngoingThis study is testing whether specific genetic markers in a patient's tumor can predict if they will respond well to immunotherapy drugs. It is for people with advanced bladder cancer that has spread and has stopped responding to standard chemotherapy. Participants receive two im…
Matched conditions: LOCALLY ADVANCED URETHRAL UROTHELIAL CARCINOMA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Apr 01, 2026 18:41 UTC
-
Heart drug joins fight against bladder cancer
Disease control OngoingThis study is testing if adding a common, low-cost blood pressure medication called propranolol to standard immunotherapy helps people with advanced bladder cancer. Six participants will receive either immunotherapy alone or immunotherapy plus propranolol. The main goal is to see…
Matched conditions: LOCALLY ADVANCED URETHRAL UROTHELIAL CARCINOMA
Phase: PHASE2 • Sponsor: Emory University • Aim: Disease control
Last updated Apr 01, 2026 14:41 UTC
-
Cancer trial asks: can patients stop treatment sooner and stay well?
Disease control OngoingThis study is for people with advanced bladder cancer who have already had about a year of immunotherapy. It compares two approaches: continuing the immunotherapy treatment versus stopping it. The main goal is to see if stopping treatment leads to similar survival rates while pot…
Matched conditions: LOCALLY ADVANCED URETHRAL UROTHELIAL CARCINOMA
Phase: PHASE3 • Sponsor: Alliance for Clinical Trials in Oncology • Aim: Disease control
Last updated Apr 01, 2026 14:41 UTC
-
New drug duo targets tough bladder cancers
Disease control OngoingThis early-stage trial is testing a combination of two targeted drugs, erdafitinib and enfortumab vedotin, for people with advanced bladder cancer that has spread and has specific genetic changes (FGFR2/3). The main goals are to find the safest and most effective dose of the drug…
Matched conditions: LOCALLY ADVANCED URETHRAL UROTHELIAL CARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 23, 2026 15:19 UTC
-
New hope for tough bladder cancers: can a combo outsmart tumors?
Disease control OngoingThis study is for people with advanced bladder cancer that has spread or come back and cannot be treated with cisplatin. It is testing if adding a chemotherapy drug (eribulin) to an immunotherapy drug (atezolizumab) works better and is safe compared to using the immunotherapy alo…
Matched conditions: LOCALLY ADVANCED URETHRAL UROTHELIAL CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 19, 2026 14:55 UTC
-
New cancer combo aims to supercharge immune system while taming side effects
Disease control OngoingThis study is testing a combination of three immunotherapy drugs—tocilizumab, ipilimumab, and nivolumab—in patients with advanced melanoma, non-small cell lung cancer, or bladder cancer. The main goal is to see if adding tocilizumab can help manage the serious side effects someti…
Matched conditions: LOCALLY ADVANCED URETHRAL UROTHELIAL CARCINOMA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Mar 16, 2026 15:26 UTC